Platelet refractoriness, FNAIT and neutrophil antigens
16 min
- Calculate a corrected count increment with the stated platelet-dose units
- Choose the next investigation for repeated poor platelet increments
- Match maternal platelet antibodies to paternal platelet antigens in suspected FNAIT
- Match HNA antibodies to HNA antigens in neonatal neutropenia and TRALI workups
Try first
Get the idea
The corrected count increment
CCI = (posttransfusion platelet count − pretransfusion platelet count, in platelets/µL) × body surface area (m²) ÷ platelet dose (number of 10¹¹ platelets). A dose of 3 × 10¹¹ platelets enters as 3, and refractoriness is assessed on counts drawn 10 to 60 minutes after transfusion. Keep both counts in platelets/µL. In a patient without fever or bleeding, a CCI above 7,500 on a count drawn 10 to 60 minutes after transfusion is the usual response. A CCI below 5,000 with supporting antibody results may point to immune refractoriness.1,2
Refractoriness
Refractoriness is a repeated poor response. One low count cannot show it. Bleeding, fever, sepsis, disseminated intravascular coagulation and an enlarged spleen cause most poor increments. The evidence is low CCIs from timed counts after two transfusions in a row.1,2 When low increments persist after those causes are assessed, the laboratory tests for HLA class I and human platelet antigen (HPA) antibodies and obtains the patient's HLA type. Platelets are then chosen by crossmatch, by HLA match, or by avoiding the antigens the antibodies recognize.2
An antibody and its antigen
Three investigations follow one logic. Find the antibody, then show the antigen it targets on the cells that were injured.
| Investigation | Antibody from | Antigen on |
|---|---|---|
| Fetal and neonatal alloimmune thrombocytopenia (FNAIT) | The mother | The fetus's platelets, inherited from the father |
| Alloimmune neonatal neutropenia | The mother | The infant's neutrophils, inherited from the father |
| Immune TRALI | The donor | The recipient's white cells |
In FNAIT, anti-HPA-1a causes about 75% to 80% of cases in people of European ancestry.5 A routine panel detects antibodies only to its own antigens. A crossmatch of the mother's serum with the father's platelets can find an antibody to a rare paternal antigen. When the first testing is negative and suspicion stays high, the reference laboratory retests 2 to 8 weeks after delivery.4,5
Human neutrophil antigen (HNA) testing needs fresh granulocytes, usually within 24 hours, at a specialized laboratory. The granulocyte immunofluorescence test (GIFT) and the granulocyte agglutination test (GAT) are used together. GIFT alone can miss anti-HNA-3a, the antibody linked to severe transfusion-related acute lung injury (TRALI).3 TRALI is classified from the clinical findings. A donor antibody that matches a recipient antigen supports the immune mechanism and guides the donor evaluation.6
References
- Association for the Advancement of Blood & Biotherapies, American Red Cross, America's Blood Centers, Armed Services Blood Program. Circular of Information for the Use of Human Blood and Blood Components. June 2024. Accessed September 27, 2026.
- Cohn CS. Platelet transfusion refractoriness: how do I diagnose and manage? Hematology Am Soc Hematol Educ Program. 2020;2020(1):527-532. doi:10.1182/hematology.2020000137
- Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee. Chapter 17: granulocyte immunology. Guidelines for the Blood Transfusion Services in the United Kingdom. Accessed September 27, 2026.
- Petermann R, Bakchoul T, Curtis BR, Mullier F, Miyata S, Arnold DM; Subcommittee on Platelet Immunology. Investigations for fetal and neonatal alloimmune thrombocytopenia: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16(12):2526-2529. doi:10.1111/jth.14294
- Sachs UJ, Bedei I, Wienzek-Lischka S, et al. Diagnosis and management of fetal and neonatal alloimmune thrombocytopenia: an update 2025. Transfus Med Hemother. 2025;52(5):318-333. doi:10.1159/000547985 Accessed September 27, 2026.
- Vlaar APJ, Toy P, Fung M, et al. A consensus redefinition of transfusion-related acute lung injury. Transfusion. 2019;59(7):2465-2476. doi:10.1111/trf.15311
Watch one
Omar Castellanos, 47 (MRN 2951406), is in induction therapy for acute myeloid leukemia. His body surface area is 1.9 m². He has no fever, no bleeding, no sign of disseminated intravascular coagulation and no enlarged spleen on record. He receives apheresis platelets on two days in a row.
- Transfusion 1: 3.2 × 10¹¹ platelets. Count 5,000/µL before, 9,000/µL 30 minutes after.
- Transfusion 2: 3.6 × 10¹¹ platelets. Count 6,000/µL before, 10,000/µL 45 minutes after.
Does his pattern call for antibody testing?
- Check the draw times: 30 and 45 minutes, both inside the window.
Only a count drawn 10 to 60 minutes after the transfusion shows whether the platelets circulated at all.
- CCI 1 = (9,000 − 5,000) × 1.9 ÷ 3.2 = 2,375.
The CCI adjusts the rise for his size and for the dose he received.
- CCI 2 = (10,000 − 6,000) × 1.9 ÷ 3.6 = 2,111.
Refractoriness needs a repeated poor response, so the second transfusion is scored the same way.
- Review the nonimmune causes: none is recorded.
Nonimmune causes explain most poor increments and are assessed before antibody testing.
- Send HLA class I and HPA antibody testing, and obtain his HLA type.
Two timed CCIs below 5,000 with no nonimmune cause fit immune refractoriness, and the antibody results choose the platelets.
Your turn
Use it
- A 66-year-old man receives one unit of plasma before a procedure.
- Within 2 hours he has severe hypoxemia, new bilateral infiltrates and a blood pressure of 88/50 mm Hg.
- His fluid balance is even, and his BNP is within the reference interval.
- The clinical team and the transfusion service classify the reaction as TRALI and report it to the collecting facility.
- The donor, a woman with four past pregnancies, is tested for granulocyte and HLA antibodies.
The clue that settled this case is the matching pair: the donor's anti-HNA-3a and the recipient's HNA-3a antigen. The pair explains the injury, and GAT was the method that could find it. The TRALI classification itself rests on the clinical findings, with or without an antibody.
Results
- Calculate a corrected count increment with the stated platelet-dose units
- Choose the next investigation for repeated poor platelet increments
- Match maternal platelet antibodies to paternal platelet antigens in suspected FNAIT
- Match HNA antibodies to HNA antigens in neonatal neutropenia and TRALI workups
To review
6 questions from this step will come back in Review.
Next step: Stem cell products and apheresisReview nowOpen the part
Keep
Sources checked
The rest of this step
A short briefing, a demonstration at the bench, 3 practice problems and a short case.
A free account opens the rest and keeps your progress.